指南与共识慢性肾脏病

欧洲共识:骨转换标志物在CKD相关骨质疏松管理中的应用

Bone turnover markers in the management of CKD-associated osteoporosis-a European consensus.
指南 / 共识 · Nephrol Dial Transplant · 2026-01-01

该共识由ERA、IOF、EFLM和ESPN工作组制定,针对慢性肾脏病(CKD)相关骨质疏松,推荐骨特异性碱性磷酸酶和抗酒石酸酸性磷酸酶5b作为可靠骨转换标志物,并提供了骨转换异常的具体诊断范围,用于风险预测、治疗选择和疗效评估。

要点

  • 骨特异性碱性磷酸酶和TRAP5b不经肾脏清除,是CKD骨评估的可靠标志物。
  • 完整I型胶原N端前肽也可用于CKD。
  • 共识提供了骨转换异常的具体诊断范围,用于风险预测和治疗决策。

核心结论

  • 骨特异性碱性磷酸酶和TRAP5b被推荐为CKD相关骨质疏松的参考骨转换标志物。
  • 共识提供了骨转换异常的具体诊断范围,并描述了BTM在风险预测、治疗策略选择和疗效评估中的临床价值。

研究设计与样本

  • 共识由欧洲肾脏协会(ERA)、国际骨质疏松基金会(IOF)、欧洲临床化学和实验室医学基金会(EFLM)和欧洲儿科肾脏病学会(ESPN)相关工作组制定。

主要发现

  • 骨特异性碱性磷酸酶和TRAP5b不经肾脏清除,被认为是CKD相关骨质疏松骨评估的可靠诊断工具。
  • 近期一个国际联盟已将骨特异性碱性磷酸酶和TRAP5b提议为CKD的参考骨转换标志物。
  • 完整I型胶原N端前肽也可用于CKD。

关键数值与推荐

  • 共识提供了骨转换异常的具体诊断范围。

临床怎么用

  • BTM可用于CKD相关骨质疏松的风险预测、治疗策略选择和疗效评估。

局限性

  • 当前临床实践指南缺乏CKD背景下骨转换的具体治疗目标。
  • 未来研究应聚焦于参考BTM与其他诊断工具的整合、具体治疗目标的建立及实现这些目标的治疗策略开发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bone turnover abnormalities are common in chronic kidney disease (CKD) and contribute to bone fragility. Recently, the Kidney Disease: Improving Global Outcomes (KDIGO) introduced the term CKD-associated osteoporosis to describe bone fragility in CKD and highlighted the role of bone turnover markers (BTM) in clinical evaluation and management of bone fragility. However, current clinical practice guidelines lack specific treatment targets for bone turnover in the setting of CKD. The aim of this consensus was to present recommendations for the use of BTM in the management of CKD-associated osteoporosis. The consensus was conducted by members of relevant working groups of the European Renal Association (ERA), International Osteoporosis Foundation (IOF), European Foundation for Clinical Chemistry and Laboratory Medicine (EFLM) and European Society of Pediatric Nephrology (ESPN). Bone-specific alkaline phosphatase and tartrate resistant acid phosphatase isoform 5b are not renally cleared and considered reliable diagnostic tools for bone evaluation in CKD-associated osteoporosis. Both have been proposed as reference BTM in CKD by a recent international consortium. Intact N-terminal telopeptide of type I collagen can also be used in CKD. The current consensus describes methodological considerations and the clinical usefulness of BTM in risk prediction, choice of therapeutic strategy, and treatment evaluation in CKD-associated osteoporosis. Specific diagnostic ranges for bone turnover abnormalities are provided. Future research should focus on the integration of these reference BTM with other diagnostic tools, establishment of concrete treatment targets, and development of treatment strategies to reach these targets.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Haarhaus M, Jørgensen HS, Bacchetta J, et al. Bone turnover markers in the management of CKD-associated osteoporosis-a European consensus. Nephrol Dial Transplant. 2026. PMID: 41700725. doi:10.1093/ndt/gfag033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。